Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army
Merck
Novartis
Boehringer Ingelheim
Daiichi Sankyo
Healthtrust
Johnson and Johnson
Express Scripts
Chinese Patent Office

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,735,403

« Back to Dashboard

Summary for Patent: 8,735,403
Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/249,066
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 8,735,403

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,735,403

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,206,189 Inhibitors of bruton's tyrosine kinase ➤ Subscribe
9,133,201 Inhibitors of Bruton's tyrosine kinase ➤ Subscribe
8,748,438 Inhibitors of Bruton's tyrosine kinase ➤ Subscribe
8,497,277 Inhibitors of Bruton's tyrosine kinase ➤ Subscribe
8,658,653 Inhibitors of Bruton's tyrosine kinase ➤ Subscribe
8,399,470 Inhibitors of bruton's tyrosine kinase ➤ Subscribe
7,514,444 Inhibitors of bruton's tyrosine kinase ➤ Subscribe
9,409,911 Inhibitors of bruton's tyrosine kinase ➤ Subscribe
8,741,908 Inhibitors of bruton's tyrosine kinase ➤ Subscribe
8,883,435 Inhibitors of Bruton's tyrosine kinase ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,735,403

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2530083 ➤ Subscribe
Slovenia 2529621 ➤ Subscribe
Slovenia 2526934 ➤ Subscribe
Slovenia 2526933 ➤ Subscribe
Slovenia 2526771 ➤ Subscribe
Slovenia 2201840 ➤ Subscribe
Slovenia 2081435 ➤ Subscribe
Singapore 10201508035T ➤ Subscribe
Singapore 10201503235V ➤ Subscribe
Singapore 166093 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Julphar
Healthtrust
Cerilliant
Novartis
Express Scripts
Fuji
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot